The gap between what CBD marketing claims and what the clinical evidence demonstrates is large — but that evidence is not empty, and understanding what it actually shows is more useful than either dismissal or uncritical acceptance.
Cannabidiol (CBD) is now one of the most widely sold dietary supplement ingredients globally, carried in pharmacies, health food stores, and online retailers across dozens of countries including Thailand, the Czech Republic, and throughout Southeast Asia. The regulatory and scientific landscape around CBD and non-intoxicating cannabinoids is evolving rapidly and unevenly — claims that were reasonable in 2019 have since been tested in large clinical trials, and some of them have not held up. This article summarizes the state of the evidence as of mid-2026.
1. What CBD Is — And What It Is Not
1.1 Pharmacology Basics
Cannabidiol is a phytocannabinoid — a naturally occurring compound in the Cannabis sativa plant, found in both drug-type cannabis and hemp (high-CBD, low-THC varieties). Unlike THC (delta-9-tetrahydrocannabinol), CBD does not act as a direct agonist at cannabinoid CB1 receptors, which is why it does not produce intoxication at typical doses.
CBD’s pharmacological activity is complex and not fully mapped. Established mechanisms include:
- TRPV1 receptor agonism: Vanilloid receptor activation at high concentrations, associated with pain and inflammation modulation
- 5-HT1A receptor agonism: Partial agonist activity at serotonin 1A receptors, relevant to anxiolytic effects
- GPR55 antagonism: The “orphan receptor” GPR55 responds to cannabinoids; CBD blocks it, which may influence bone density and inflammation
- Inhibition of endocannabinoid reuptake: CBD inhibits the reuptake of anandamide, effectively increasing endocannabinoid signaling without directly activating cannabinoid receptors
The consequence of this multi-target pharmacology: CBD’s effects are real but dose-dependent and mechanism-specific. Different effects may operate through different receptors and require different doses.
1.2 Bioavailability by Route of Administration
CBD bioavailability varies dramatically by delivery method, which substantially affects the clinical relevance of dose information:
| Route | Bioavailability | Onset | Notes |
|---|---|---|---|
| Oral (oil/capsule) | 6–19% | 1–2 hours | Wide individual variation; food increases absorption |
| Sublingual (under tongue) | 12–35% | 15–45 min | Partial absorption, remainder swallowed |
| Inhalation (vapor) | 31–45% | 1–5 min | Fastest onset; lung health considerations |
| Topical | <1% systemic | 15–60 min | Local effect; minimal blood absorption |
| Nanoemulsion formulations | 35–80% (claimed) | 15–30 min | Company-specific; variable validation |
Source: Millar et al. (2019), Frontiers in Pharmacology.
This bioavailability range has an important practical implication: a 25 mg oral CBD capsule delivers approximately 2–5 mg of CBD into circulation. Many wellness products are dosed at levels where the actual systemic concentration is below that of trials showing effect. This is not always disclosed in marketing.
2. What the Evidence Shows
2.1 Established (Pharmaceutical-Grade Evidence)
Epilepsy — FDA-approved Epidiolex (pharmaceutical CBD): Multiple randomized controlled trials demonstrate efficacy of high-dose pharmaceutical CBD (10–20 mg/kg/day) for Dravet syndrome and Lennox-Gastaut syndrome — rare and severe childhood epilepsy syndromes. This evidence is robust and has led to regulatory approval in the US, EU, and several other jurisdictions.
The relevance of this evidence to wellness CBD products: limited. Epidiolex delivers consistent, high doses of pharmaceutical-grade CBD with assured bioavailability. Wellness products deliver variable, generally lower doses of less-standardized preparations. The epilepsy evidence does not directly translate to claims about wellness-dose CBD for anxiety or sleep in healthy adults.
2.2 Suggestive (Phase 2 Trials or Multiple Positive Randomized Trials)
Anxiety: Multiple randomized controlled trials have found anxiolytic effects of CBD. A meta-analysis by Kayser et al. (2024) found significant effect of CBD on anxiety measures across 10 RCTs, with higher response rates at doses of 300–600 mg/day than at lower doses typically used in wellness products. The evidence is more consistent at higher doses than those used in most commercial products.
Sleep: Shannon et al. (2019) found CBD at 25–175 mg improved sleep scores in a retrospective case series. Subsequent RCTs have shown inconsistent results — some positive effects on sleep quality and anxiety-related sleep disturbance, others showing no difference from placebo. The sleep evidence is promising but not definitive as of 2026.
Inflammation and joint pain: Preclinical animal models strongly support anti-inflammatory effects. Human trials in rheumatoid arthritis (Blake et al., 2006, the first and still one of the few rigorous arthritis trials) found significant improvement in pain on movement and resting. Subsequent trials in osteoarthritis and chronic pain are mixed, partly due to dose variability.
2.3 Weak or Inconsistent Evidence
General wellness and mood: No strong RCT evidence supports CBD supplementation improving general wellbeing, energy, or mood in healthy individuals without clinical conditions.
Topical CBD for skin conditions and pain: Very limited human trial data. Preclinical support exists for skin inflammation applications, but penetration of CBD through intact skin to systemic circulation is minimal. Effect is likely local at best.
Athletic recovery: Multiple observational studies and athlete surveys show widespread CBD use for recovery and pain, but randomized controlled trials are sparse and results are mixed.
3. Other Non-Intoxicating Cannabinoids
3.1 CBG (Cannabigerol)
The “stem cell” cannabinoid — CBGA is the biosynthetic precursor to all other cannabinoids. CBG itself is present in low concentrations in most cannabis/hemp, but CBG-dominant varieties have been developed.
Current evidence: primarily preclinical. Studies in cell and animal models suggest antibacterial activity (particularly against MRSA — Appendino et al., 2008), neuroprotective potential, anti-inflammatory properties, and appetite stimulation effects. Human clinical trial data as of 2026 is very limited. CBG products are largely outpacing the evidence base.
3.2 CBN (Cannabinol)
CBN forms through oxidative degradation of THC — old cannabis with degraded THC contains higher CBN. It has weak agonist activity at CB1 (roughly 10% of THC potency) and is sometimes marketed as a sleep aid.
Evidence: Kaul et al. (2021) found no significant sleep-promoting effect of CBN alone in a controlled trial with healthy volunteers. The popular “CBN for sleep” claim has very limited direct support. A 2024 randomized trial by Tringale and Jensen found improved self-reported sleep quality with a CBD:CBN combination (1:1 ratio) versus CBD alone, suggesting the combination may have additive effects.
3.3 CBC (Cannabichromene)
Preclinical evidence for anti-inflammatory and analgesic effects, and potential antidepressant-like activity in rodent models. Human evidence: essentially absent. CBC is present in the “entourage” of full-spectrum hemp extracts but has not been isolated and tested in meaningful human trials.
3.4 THCV (Tetrahydrocannabivarin)
A propyl analog of THC with complex receptor pharmacology — partial antagonist at CB1 at low doses, partial agonist at high doses. Preclinical evidence suggests potential in appetite suppression, blood glucose regulation, and epilepsy. One randomized trial (Jadoon et al., 2016) found improved glycemic parameters in type 2 diabetes patients. More human data is needed before strong claims are appropriate.
4. Full-Spectrum vs. Broad-Spectrum vs. Isolate
4.1 The Entourage Effect Hypothesis
The “entourage effect” — the proposition that whole-plant cannabis extracts are more therapeutically effective than isolated cannabinoids because of synergistic interactions between cannabinoids, terpenes, and other phytochemicals — is frequently cited in CBD marketing.
The scientific basis: Russo (2011) published an influential hypothesis paper outlining how terpenes might modulate cannabinoid receptor activity. This has been partially supported by cell culture and animal model work. Human trial data specifically comparing isolate versus full-spectrum at equivalent CBD doses is limited, and the trials that exist show mixed results.
Assessment: the entourage effect hypothesis is plausible and has partial preclinical support. It should not be treated as proven in the way it is often presented. The presence of additional terpenes and minor cannabinoids in full-spectrum extracts may contribute meaningfully to effect — or the effect may be primarily CBD-driven. The answer may also vary by condition and individual.
4.2 Practical Product Selection
From a consumer perspective:
- Full-spectrum: Contains all naturally occurring cannabinoids including trace THC (hemp grown in the EU may contain up to 0.3% THC; Thailand applies a 0.2% THC limit to extracts). Potentially benefiting from entourage effect. The trace THC accumulates with chronic high-dose use and may produce detectable levels in drug testing.
- Broad-spectrum: THC removed but other cannabinoids and terpenes retained. Good compromise for those with drug testing concerns.
- Isolate: Pure CBD, no other cannabinoids. Highest purity, least drug testing risk, but potentially missing synergistic components.
4.3 Certificate of Analysis (COA) Basics
Any CBD product from a reputable vendor should provide a third-party laboratory Certificate of Analysis confirming:
- Cannabinoid potency: Actual CBD content, THC content, other cannabinoids detected
- Heavy metals: Lead, mercury, arsenic, cadmium — hemp accumulates soil contaminants
- Pesticides: Screen for agricultural chemical residues
- Microbials: Bacteria, yeast, mold counts
Products without a current, third-party COA should be viewed with caution. The supplement industry in most countries (including Thailand and Vietnam) does not pre-market test products, making COAs the primary consumer quality assurance tool.
5. Dosing Considerations
5.1 Why Dose Recommendations Are Imprecise
Standard dose recommendations for wellness CBD (10–50 mg/day) are based on convention, product economics, and extrapolation from trial data, not from dose-finding studies in the specific populations at which wellness products are targeted. The dose-response relationship for CBD in anxiety, sleep, and pain is complex and non-linear in some human studies.
What is known:
- Very low doses (<10 mg/day from oral products with typical bioavailability) are likely below clinically meaningful thresholds for most individuals
- Doses of 150–300 mg/day have the best evidence base for anxiety effects
- Pharmaceutical-grade CBD trials use 10–25 mg/kg/day for epilepsy — 100–2000+ mg/day for adult weight ranges
- There is a gap between effective pharmaceutical doses and typical supplement doses that should prompt consumer awareness
5.2 Drug Interactions
CBD is metabolized by CYP450 liver enzymes (particularly CYP3A4 and CYP2C9) and inhibits these enzymes at higher doses. This means CBD can increase or decrease blood levels of other medications metabolized through the same pathways. Clinically relevant interactions have been documented with:
- Anticoagulants (warfarin) — increased blood levels, increased bleeding risk
- Anti-epileptic medications (clobazam, valproate) — elevated drug levels
- Some immunosuppressants and cardiac medications
Anyone taking prescription medications should consult their prescribing physician before beginning regular CBD use at higher doses.
6. Regulatory Status — Southeast Asia and Czech Republic Context
6.1 Thailand
Thailand legalized hemp cultivation and hemp-derived CBD products in 2021, and the landscape has since evolved. As of 2026, CBD derived from hemp (Cannabis sativa with THC content not exceeding 1.0% by weight in raw material) is legal for sale in food, cosmetics, and dietary supplements with appropriate licensing under Food and Drug Administration rules. Thai farmers may grow licensed hemp varieties, and CBD extract businesses operate with licensing from relevant ministries.
Restrictions: THC in final products must not exceed 0.2% (food) or established limits per product category. Claims of medical therapeutic benefit remain strictly regulated.
6.2 Czech Republic
The Czech Republic and EU framework: in the EU, industrial hemp may be grown from registered varieties with THC content not exceeding 0.3% (the limit was 0.2% before 1 January 2023). Since 1 January 2022 the Czech Republic has set a higher national limit of 1% THC in dried matter for technical hemp. CBD used as a food or food supplement ingredient is a novel food under the EU Novel Food Regulation and requires authorization before it can be sold — enforcement varies by member state. Czech regulation follows EU framework with some national implementation specifics.
Summary
CBD is a pharmacologically active compound with real clinical effects that have been demonstrated in adequate trials, primarily for anxiety at moderate-to-high doses and for epilepsy at pharmaceutical doses. The wellness product market substantially oversells the evidence, particularly for low-dose products making broad health claims. The path to informed CBD use requires: realistic understanding of bioavailability, selection of products with third-party COA verification, dose calibration toward the evidence base, and awareness of drug interaction potential for individuals on medications.
7. Terpenes and the Broader Phytochemical Picture
7.1 What Terpenes Are
Terpenes are the aromatic volatile compounds that give cannabis its characteristic smell — limonene (citrus), myrcene (earthy, musky), linalool (floral, lavender), beta-caryophyllene (spicy, black pepper), pinene (pine), and dozens of others. They are produced in the same trichomes that contain cannabinoids and are also found in many other plants used in traditional medicine.
Terpenes are pharmacologically active in their own right at sufficient concentrations. Beta-caryophyllene, uniquely among terpenes, directly activates CB2 cannabinoid receptors — making it technically a cannabinoid by receptor definition despite not being structurally related to THC or CBD. This gives full-spectrum extracts (which contain terpenes) potentially different pharmacological profiles than isolated CBD.
7.2 Terpene Research in Cannabis Context
Preclinical (cell culture and animal) research on cannabis-derived terpenes:
- Myrcene: Sedative effects in rodent models, potentiates barbiturate sleep time. Frequently cited for indica sedation, though direct human evidence is limited.
- Limonene: Anxiolytic effects in rodent models, potential antidepressant activity. A small RCT in human subjects with anxiety found anxiolytic effects of inhaled limonene.
- Linalool: Sedative and anxiolytic effects in several animal models. More human data exists for lavender oil (high linalool content) than for isolated linalool.
- Beta-caryophyllene: Anti-inflammatory via CB2 activation; analgesic in rodent models.
The challenge: terpene concentrations in commercial CBD products vary widely and are rarely disclosed quantitatively. “Full-spectrum” is a category, not a specification.
8. Practical Guide to Evaluating CBD Products
8.1 Reading a COA
A Certificate of Analysis from a qualified analytical laboratory tells you what is actually in the product. Key numbers to verify:
Potency panel: Confirms claimed CBD content and THC level. For a “300 mg CBD” capsule:
- Expected CBD per serving: if 30 capsules, 10 mg/capsule
- Acceptable variance from label claim: ±10–15% (wide variance indicates poor manufacturing control; >20% off is a concern)
- THC result: should be <0.2% (or <0.3% per US standards) — confirm as absolute amount, not just percentage
Heavy metals: Results in parts per billion (ppb) or parts per million (ppm). Compare against:
- Lead: <5 µg/g (ppm) in hemp extract, ideally <1 µg/g
- Mercury: <1 µg/g
- Arsenic: <3 µg/g
- Cadmium: <0.5 µg/g
Microbials: Total yeast and mold count <10,000 CFU/g; total aerobic bacteria <100,000 CFU/g; no detection of Aspergillus species.
Pesticides: No detected residues above laboratory reporting limits for pesticides listed.
8.2 Red Flags in CBD Product Marketing
Specific claims that should raise skepticism based on the current evidence base:
- “Cures [disease name]” — CBD cannot legally or factually be claimed to cure diseases except where pharmaceutical approval exists (Epidiolex for specific epilepsy syndromes)
- “100% bioavailable” — No oral or sublingual CBD product achieves this; such a claim is physically impossible
- “No side effects” — CBD has documented side effects at effective doses, including drowsiness, diarrhea, and liver enzyme elevation at high doses
- “Clinically proven” without citation — Ask for the specific clinical trial reference and verify it is peer-reviewed and relevant to the product’s dose and formulation
9. Hemp-Derived CBD in Southeast Asia
9.1 Czech Republic and EU Hemp Market
Hemp businesses in the Czech Republic operate under both the EU and the national framework for hemp-derived products. The EU defines industrial hemp as Cannabis sativa varieties with THC content not exceeding 0.3% in the plant, a limit in force since 1 January 2023 (previously 0.2%); Czech national law allows up to 1% THC for technical hemp. CBD extract products for human consumption are subject to the EU Novel Food Regulation, which requires a safety assessment and authorization before legal sale as food or food supplement.
Several EU countries have their own enforcement approaches pending full EU harmonization. The Czech Republic has historically had a pragmatic approach to hemp products while staying within EU law.
9.2 Thailand and Southeast Asian Distribution Context
Thailand’s hemp and CBD regulatory framework under FDA oversight establishes conditions for CBD products in food, cosmetics, and health products. Businesses importing, distributing or selling hemp-derived products in Thailand face a regulatory environment that has shifted significantly between 2020 and 2026 as cannabis law evolved.
Key principles for any hemp-derived product business in Thailand:
- Source only from licensed hemp cultivators or licensed extract manufacturers
- Maintain COA documentation for every batch
- Ensure THC content meets the applicable category limit (currently 0.2% in most finished product categories)
- Therapeutic claims require specific product registration and clinical evidence — wellness positioning is safer from a compliance standpoint
10. Self-Assessment: Should You Use CBD?
10.1 Who May Benefit
Based on the current evidence, CBD may offer genuine benefit for:
- Adults with clinically diagnosed anxiety disorder, particularly at doses of 150–600 mg/day under medical supervision
- People experiencing anxiety-related sleep disruption
- Individuals with inflammatory pain conditions who have not found adequate relief from standard approaches, particularly in combination with appropriate medical care
- People with treatment-resistant epilepsy syndromes (under neurological care only, using pharmaceutical-grade CBD)
10.2 Who Should Exercise Caution
- People on prescription anticoagulants, anti-epileptic drugs, or immunosuppressants — drug interactions are clinically significant
- Individuals with liver conditions — CBD is metabolized hepatically and can elevate liver enzymes at higher doses
- Pregnant or breastfeeding women — insufficient safety data
- People under 18 — developing endocannabinoid system; pharmaceutical CBD for epilepsy is justified by clinical necessity; wellness use is not recommended
10.3 Starting Point for New Users
If proceeding:
- Start at 25–50 mg/day oral CBD from a COA-verified product
- Maintain the dose for 2–4 weeks before evaluating effect — CBD effects are not acute for most wellness applications
- Increase dose by 25–50 mg every 2 weeks if no benefit and no adverse effects
- Keep a simple daily log of the symptom you are targeting, sleep quality, and any side effects
- If taking any prescription medication, consult your prescribing physician before starting
References
- Millar, S. A., et al. (2019). A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology, 10, 1365.
- Kayser, R. R., et al. (2024). A meta-analysis of cannabidiol effects on anxiety. Journal of Psychopharmacology, 38(3), 247–259.
- Shannon, S., et al. (2019). Cannabidiol in anxiety and sleep: a large case series. Permanente Journal, 23, 18–041.
- Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
- Appendino, G., et al. (2008). Antibacterial cannabinoids from Cannabis sativa. Journal of Natural Products, 71(8), 1427–1430.
- Tringale, R., & Jensen, C. (2024). CBD and CBN combination effects on sleep quality. Journal of Cannabis Research, 6(1), 12.